News & Topics Past News
2015.08.28
Onconova Announces Submission of European Clinical Trial Applications for IV Rigosertib Pivotal Phase 3 Trial in Higher-Risk MDS
2015.08.17
Onconova to Present Results from Phase 2 Study of Oral Rigosertib in Combination with Azacitidine for MDS and AML Patients
2015.08.17
Onconova Announces Submission of IND for IV Rigosertib Pivotal Phase 3 Trial in Higher-Risk MDS
2015.08.05
Analyst Report: Shared Research updates the report
2015.08.05
Summary of Financial Results For the Second Quarter of Fiscal Year Ending December 31, 2015[Japanese GAAP](Non-consolidated)
2015.08.05
Notice Concerning Non-operating income
2015.06.26
Completion of Japan Phase I Trial for Oral Rigosertib (SyB C-1101) in MDS
2015.05.07
Analyst Report: Shared Research updates the report
2015.05.07
Summary of Financial Results for the First Quarter of Fiscal Year Ending December 31, 2015[Japanese GAAP](Non-consolidated)
2015.05.07
Notice Concerning Non-operating Expense
2015.04.10
Notice Concerning Finalized Details on Issuance of Stock Acquisition Rights (Stock Option) to the Company's Directors
2015.04.10
Notice Concerning Finalized Details on Issuance of Stock Acquisition Rights (Stock Option) to the Company's Employees
2015.03.27
Notice of Shareholder Voting Results for the 10th Ordinary General Meeting of Shareholders
2015.03.26
Notice Concerning the Issuance of Stock Acquisition Rights as Stock Option to Directors
2015.03.26
Notice Concerning the Issuance of Stock Acquisition Rights as Stock Option to Employees
2015.03.26
Notice of Director and Auditor Appointments
2015.03.23
Analyst Report: Shared Research updates the report
2015.03.18
Notice Concerning Change in Status of Major shareholder
2015.03.06
Information on Shareholders' Meeting: Updated the Page
2015.03.05
Notice of Nomination of Director Candidates and Auditor Candidates
2015.02.12
Analyst Report: Shared Research updates the report
2015.02.10
SymBio's Long Range Plan: FY2015 to FY2017
2015.02.10
Summary of Financial Statements for the Fiscal Year Ended December 31, 2014[Japanese GAAP] (Non-consolidated)